AbbVie
ABBV
3,834 hedge funds and large institutions have $270B invested in AbbVie in 2025 Q1 according to their latest regulatory filings, with 265 funds opening new positions, 1,498 increasing their positions, 1,631 reducing their positions, and 126 closing their positions.
110% more first-time investments, than exits
New positions opened: 265 | Existing positions closed: 126
46% more funds holding in top 10
Funds holding in top 10: 168 → 245 (+77)
25% more capital inflows, than outflows
Capital inflows: $11.3B | Capital outflows: $9.03B
15% more call options, than puts
Call options by funds: $3.94B | Put options by funds: $3.44B
2% more funds holding
Funds holding: 3,757 → 3,834 (+77)
0.51% more ownership
Funds ownership: 72.31% → 72.82% (+0.51%)
8% less repeat investments, than reductions
Existing positions increased: 1,498 | Existing positions reduced: 1,631
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.08B |
| 2 |
BlackRock
New York
|
+$747M |
| 3 |
JP Morgan Chase
New York
|
+$582M |
| 4 |
Goldman Sachs
New York
|
+$555M |
| 5 |
Barclays
London,
United Kingdom
|
+$531M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$1.55B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$583M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$422M |
| 4 |
Amundi
Paris,
France
|
-$328M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$260M |
ABBV Hedge Fund Activity: Q1 2025 in Review
3,834 of the 7,486 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2025, worth a combined $270B — up 19% from $227B a quarter earlier.
Buyers outnumbered sellers: 265 funds opened new ABBV positions and 126 closed out — a net gain of 139 holders — while 1,498 added to existing stakes and 1,631 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.08B. The largest seller was Capital International Investors, cutting an estimated $1.55B.
- 3,834 institutional investors held AbbVie (ABBV) as of Q1 2025, up from 3,757 in Q4 2024.
- Funds reported $270B of AbbVie stock for Q1 2025, up 19% quarter-over-quarter.
- 265 funds opened new AbbVie positions in Q1 2025 and 126 closed out, a net change of +139 holders.
- The largest AbbVie buyer in Q1 2025 was Fidelity Investments, an estimated $1.08B added.
- The largest AbbVie seller in Q1 2025 was Capital International Investors, an estimated $1.55B sold.
Based on aggregated 13F filings for Q1 2025.